During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed how to implement use of bispecific T-cell engagers in ...

Panelists discuss how chronic graft-versus-host disease severity can be stratified to guide the tailoring of systemic treatments and supportive care strategies for optimal patient management.

Panelists discuss how a case study illustrates the multisystem manifestations of chronic graft-versus-host disease and demonstrate the application of NIH organ-specific scoring for comprehensive ...

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small ...

The bispecific T-cell engager tarlatamab showed continued efficacy and tolerable safety, according to follow-up from the ...

As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the ...

In FRα-positive, platinum-resistant ovarian cancer, mirvetuximab soravtansine showed improvements in progression-free survival, overall response rate, and overall survival. Patients with FRα-positive, ...

Anil Parwani, MD, PhD, addresses potential biases or limitations in the artificial intelligence algorithm used at his institution.

The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among ...

Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult ...

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.